<DOC>
	<DOCNO>NCT01646450</DOCNO>
	<brief_summary>A single arm , open label , phase IV trial evaluate safety efficacy icotinib first-line treatment elder patient advance metastatic ( IIIb IV ) NSCLC mutate EGFR .</brief_summary>
	<brief_title>First-line Treatment With Icotinib Elder NSCLC EGFR Mutated Patients</brief_title>
	<detailed_description>A single arm , open label , prospective , phase IV trial evaluate safety efficacy icotinib first-line treatment elder patient advance metastatic ( IIIb IV ) NSCLC mutate EGFR . - Primary endpoint ass progression-free survival - Secondary endpoint ass overall survival , objective response rate , disease control rate .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Recurrent progressive NonSmall Cell Lung Cancer stage IV IIIB patient . Positive EGFR Mutation . No previous systemic anticancer therapy . Male female patient age 70 year . Measurable lesion accord RECIST least one measurable lesion previously irradiate , unless disease progression document site . Provision write informed consent . Evidence clinically active Interstitial Lung Diseases ( Patients chronic , stable , radiographic change asymptomatic need exclude ) . Known severe hypersensitivity icotinib excipients product . Evidence significant clinical disorder laboratory find make undesirable subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>EGFR Mutation</keyword>
	<keyword>Elder patient</keyword>
</DOC>